Judith M. Hyatt - Concepedia

Author

Judith M. Hyatt

Kaleida Health

Also Known As

J HYATT, J M Hyatt, Judith M Hyatt, Judith M. Hyatt, Julia Hyatt

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Kaleida Health University at Buffalo, State University of New York Millard Fillmore Suburban Hospital

About

Judith M. Hyatt is an author at Kaleida Health specializing in clinical microbiology, drug resistance, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	3	3	164
2	Medicine	3	3	164
3	Antibiotics	2	2	152
4	Microbiology	1	1	139
5	Pulmonary Medicine	1	1	12

Judith M. Hyatt

Publications

946

Citations

H-Index

Page 1

	Year	Citations
Pharmacodynamic Evaluation of Factors Associated with the Development of Bacterial Resistance in Acutely Ill Patients during Therapy Jennifer Thomas, Alan Forrest, Sujata M. Bhavnani, Antimicrobial Agents and Chemotherapy	1998	512
Genesis of Methicillin‐Resistant<i>Staphylococcus aureus</i>(MRSA), How Treatment of MRSA Infections Has Selected for Vancomycin‐Resistant<i>Enterococcus faecium,</i>and the Importance of Antibiotic Management and Infection Control Jerome J. Schentag, Judith M. Hyatt, James R. Carr, Clinical Infectious Diseases Enterococcus FaeciumAntibiotic ResistanceDrug ResistanceAntimicrobial StewardshipHealthcare-associated Infection	1998	139
Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar Judith M. Hyatt, David E. Nix, Jerome J. Schentag Antimicrobial Agents and Chemotherapy	1994	80
In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa Judith M. Hyatt, David E. Nix, Charles W. Stratton, Antimicrobial Agents and Chemotherapy	1995	46
Neural correlates of adherence to extended-release naltrexone pharmacotherapy in heroin dependence A.L. Wang, Igor Elman, Steven B. Lowen, Translational Psychiatry	2015	43
Pharmacodynamic Modeling of Risk Factors for Ciprofloxacin Resistance in <i>Pseudomonas aeruginosa</i> Judith M. Hyatt, Jerome J. Schentag Infection Control and Hospital Epidemiology	2000	40
In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoiding resistance. Jerome J. Schentag, Mary C. Birmingham, Joseph A. Paladino, PubMed	1997	32
Comparative Pharmacokinetics of Oral Ceftibuten, Cefixime, Cefaclor, and Cefuroxime Axetil in Healthy Volunteers David E. Nix, William T. Symonds, Judith M. Hyatt, Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy	1997	29
Modeling the response of pneumonia to antimicrobial therapy Judith M. Hyatt, Aileen B Luzier, Alan Forrest, Antimicrobial Agents and Chemotherapy Health SciencesAntibioticsBacterial EradicationKlebsiella PneumoniaeStudies Eradication	1997	13
Pharmacokinetic/pharmacodynamic predictors of time to clinical resolution in patients with acute bacterial exacerbations of chronic bronchitis treated with a fluoroquinolone Barbara Meinl, Judith M. Hyatt, Alan Forrest, International Journal of Antimicrobial Agents Clinical ResolutionHealth SciencesChronic BronchitisRespiratory InfectionInfectious Respiratory Disease	2000	12

Page 1